Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of oral semaglutide on glucose variability and oxidative stress in type 2 diabetes
jRCT1031210620Completed
- Sponsor
- SHOWA Medical University Hospital
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by SHOWA Medical University Hospital. Primary endpoint: Change in d-ROMs at 24 weeks. Started Feb 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031210620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210620.